-
CONFERENCE PDF
POSTER

Determination of phenotypic clinical cut-offs for etravirine (ETR): pooled Week
24
results of the DUET-1 and DUET-2 trials
M Peeters, S Nijs, J Vingerhoets, et al
2008 International
HIV Drug Resistance Workshop
-
CONFERENCE PDF
POSTER

Nucleoside-associated mutations cause hypersusceptibility to etravirine (ETR)
G Picchio, J Vingerhoets, N Parkin, et al
2008 International
HIV Drug Resistance Workshop
-
CONFERENCE PDF
POSTER

An update of the list of NNRTI mutations associated with decreased virologic
response to
etravirine (ETR): multivariate analyses on the pooled DUET-1 and DUET-2 clinical
trial data
J Vingerhoets, M Peeters, H Azijn, et al
2008 International
HIV Drug Resistance Workshop
-
CONFERENCE
POWERPOINT
PRESENTATION
Pooled 48-Week Analysis of DUET-1 and DUET-2: Durable Efficacy and Safety
Results of Etravirine (ETR; TMC125) in
Treatment-Experienced HIV-infected Patients
A Cheret, C Katlama, B Trottier, et al ISHEID 2008
|